Citations

Clear

6422 citation(s) found for "Su, Christopher".

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Bartlett, Nancy L. , Kim, Won Seog , Fleury, Isabelle , Laribi, Kamel , Bergua, Juan , Bouabdallah, Krimo , Forward, Nicholas, Bijou, Fontanet , MacDonald, David , Ghesquières, Hervé , Nowakowski, Grzegorz S. , Yasenchak, Christopher A. , Patterson, Monica, Ho, Linda , Rustia, Evelyn, Fanale, Michelle A. , Jie, Fei, Kim, Won Seog , Laribi, Kamel , Bergua, Juan Miguel , Bijou, Fontanet , MacDonald, David , Portell, Craig A , Nowakowski, Grzegorz S , Yasenchak, Christopher A , Bartlett, Nancy L , Hahn, Uwe, Laribi, Kamel , Portell, Craig A. , Kim, Jeong‐Ah

Mayo Clinic

Journal of Clinical Oncology | January 7, 2025 | Volume: 43 | Issue: 9 | Pages: 1061-1072

10.1200/jco-24-02242 | PMID 39772655 Get It

PURPOSE In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated the efficacy and safety of BV + Len + R versus placebo + Len + R in patients with R/R DLBCL. METHODS ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo + Len + R in patients with R/R DLBCL. Patients received BV or placebo once every 3 weeks, Len once daily, and R once every 3 weeks. The primary end point was overall survival (OS), and secondary end points included investigator-assessed progression-free survival (PFS) and objective response rate (ORR). A prespecified interim analysis was performed after 134 OS events, with two-sided P = .0232 as the efficacy boundary. RESULTS Patients (N = 230) were randomly assigned to receive BV + Len + R (n = 112) or placebo + Len + R (n = 118). Two patients in the placebo arm did not receive treatment. With a median follow-up of 16.4 months, the median OS was 13.8 months with BV + Len + R versus 8.5 months with placebo + Len + R (hazard ratio, 0.63 [95% CI, 0.45 to 0.89]; two-sided P = .009). The median PFS was 4.2 months with BV + Len + R versus 2.6 months with placebo + Len + R (hazard ratio, 0.53 [95% CI, 0.38 to 0.73]; two-sided P < .001). The ORR was 64% ([95% CI, 55 to 73]; two-sided P < .001) with BV + Len + R and 42% (95% CI, 33 to 51) with placebo + Len + R; complete response rates were 40% and 19%, respectively. Treatment-emergent adverse events (AEs) occurred in 97% of patients in both arms. In both arms, the most common treatment-emergent AEs were neutropenia, thrombocytopenia, diarrhea, and anemia. CONCLUSION BV + Len + R demonstrated a statistically significant survival benefit with a manageable safety profile in heavily pretreated patients with R/R DLBCL.
Survival benefit associated with liver transplantation for hepatocellular carcinoma based on tumor burden scores at listing
Liu, Hao , Lee, Hang , Shi, Liuhua , Wang, Xixi , Powers, Colin , Li, Xingjie , Alberola, Ramon Bataller, Behari, Jaideep , Duarte‐Rojo, Andrés , Hughes, Dempsey L. , Malik, Shahid M. , Jonassaint, Naudia , Tohme, Samer , Gunabushanam, Vikraman , Tevar, Amit D. , Cruz, Ruy J. , Dharmayan, Stalin, Ayloo, Subhashini, Humar, Abhinav , Liu, Hao , Duarte-Rojo, Andres , Zhang, Wei , Di, Mengyang , Wang, Xixi, Zhang, Xingyu , Sethi, Vrishketan , Xiao, Yao , Crane, Andrew, Kaltenmeier, Christof , Geller, David A. , Hughes, Christopher L. , Molinari, Michele

Mayo Clinic

Hepatology Communications | January 7, 2025 | Volume: 9 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000619 | PMID 39774957 Get It

Introduction: Liver transplantation (LT) provides significant survival benefits to patients with unresectable HCC. In the United States, organ allocation policies for HCCs within the United Network for Organ Sharing criteria do not prioritize patients based on their differences in oncological characteristics. This study assessed whether transplant-associated survival benefits (TASBs) vary among patients with different tumor burden scores (TBS) measured at the time of listing. Methods: We analyzed data from adults applying for HCC MELD exception points between 2002 and 2019, with follow-up until December 2023, using the Scientific Registry of Transplant Recipients. TBS was determined based on the largest tumor diameter and number of HCCs. Patients were categorized into low (≤3), intermediate (3.1–5), and high (>5) TBS groups. TASB was measured as the difference in 5-year survival with and without LT. Results: This study included 36,634 LT candidates. High-TBS patients had higher waitlist dropout rates and marginally lower post-transplant survival, resulting in a significantly greater TASB. The 5-year TASB for the low, intermediate, and high TBS groups were 15.7, 22.1, and 25.0 months, respectively. The adjusted survival benefit expressed in 5-year survival differences was 21.9%, 34.5%, and 39.4% in the low, intermediate, and high TBS groups, respectively ( p <0.001). Conclusions: Higher TBS during listing correlates with greater LT benefits for patients with unresectable HCC within UNOS criteria. We conclude that organ allocation policies in the United States should prioritize patients with high TBS due to their increased risk of dropout and comparable post-transplant survival when compared to patients with less advanced tumors.
Correlation of the Sinonasal Outcome Test‐22 With the University of Washington Quality of Life in Assessing Quality of Life in Sinonasal Malignancy Utilizing a Multicenter Prospective Observational Cohort Registry
Fleseriu, Cara M. , Beswick, Daniel M. , Maoz, Sabrina L. , Hwang, Peter H. , Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Traylor, Katie , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Patel, Zara M. , Smith, Timothy L. , Wang, Marilene B. , Wang, Eric W , Beswick, Daniel , Maoz, Sabrina L , Hwang, Peter H , Humphreys, Ian M , Jafari, Aria , Kingdom, Todd T , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Choby, Garret , Kuan, Edward C , Adappa, Nithin D. , Geltzeiler, Mathew , Abuzeid, Waleed M. , Pinheiro‐Neto, Carlos , Le, Christopher H. , Lee, Jivianne K., Nayak, Jayakar V. , John, Maie A. St. , Suh, Jeffrey D. , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | January 6, 2025 | Volume: 15 | Issue: 4 | Pages: 451-454

10.1002/alr.23522 | PMID 39761380 Get It

Glucarpidase for treatment of high-dose methotrexate toxicity
Gupta, Shruti , Kaunfer, Sarah Allison , Chen, Kevin L. , Dias, Julie‐Alexia , Rajasekaran, Arun , Prosek, Jason, Truong, Huong L. , Wood, Anthony C., Bassil, Claude , Renaghan, Amanda D., Carlos, Christopher A., Kelly, Katherine J. , Passero, Christopher J., Abudayyeh, Ala , Shin, Daniel Sanghoon , Yelvington, Bradley, Kanduri, Swetha Rani , Neyra, Javier A. , Shirali, Anushree C. , Bansal, Anip, Geara, Abdallah Sassine , Mithani, Zain, Ziolkowski, Susan , Rashidi, Arash, Jakubowski, Jonathan, Pujari, Ashwini, Dotson, Emily, Wall, Sarah , Patton, John T. , Barreto, Jason N. , Sheikh, M. Salman , Lee, Jamie, Lucchesi, Nicholas, Kolman, Michael David, Rasheed, Muhammad Ahsan, Afzal, Afsheen, Mahesh, Amrita, Hsu, Raymond K. , Nicolaysen, Anthony, Tefera, Kibrewessen, Schretlen, Claire F. , Miller, Ryan M. , Velez, Juan Carlos Q. , Chandrasekhara, Soniya, Donley, Vicki, Patel, Ashka , Krishnamurthy, Shobana, Ali, Rafia, Yilmam, Osman A , Wells, Sophia L., Ortega, Jessica L. , Green‐Lingren, Olivia, Leaf, Rebecca Karp , Sise, Meghan E. , Nayak, Lakshmi , LaCasce, Ann S. , Leaf, David E. , Kaunfer, Sarah A , Rajasekaran, Arun , Shah, Chintan V , Glezerman, Ilya G , Kelly, Katherine , Abudayyeh, Ala , Neyra, Javier A , Edmonston, Daniel , Ziolkowski, Susan L , Bond, David A , Patton, John , Barreto, Jason N , Herrmann, Sandra M , Sheikh, Mohammad S , Hsu, Raymond K , Aklilu, Abinet M , Krishnamurthy, Shobana , Yilmam, Osman A , Ortega, Jessica L , LaCasce, Ann Steward , Leung, Nelson , Leaf, David E , Gupta, Shruti , Dias, Julie-Alexia , Vijayan, Anitha , Zhang, Jingjing , Drappatz, Jan , Sperati, Christopher John , Rashidi, Arash , Bond, David A. , Patton, John T. , Herrmann, Sandra M. , Baz, Rachid , Lee, Jamie, Kolman, M F , Afzal, Afsheen, Kang, Dasol, Mahesh, Amrita, Miller, Ryan M., Flannery, Alexander H , Aklilu, Abinet M. , Anand, Shuchi , Ni, Jian, Wells, Sophia L., Leung, Nelson

Mayo Clinic

Blood | January 6, 2025 | Volume: 145 | Issue: 17 | Pages: 1858-1869

10.1182/blood.2024026211 | PMID 39760780 Get It

Abstract High-dose methotrexate (MTX) results in high rates of acute kidney injury (AKI), neutropenia, and hepatotoxicity. Glucarpidase is a recombinant enzyme that cleaves MTX, but clinical data supporting its use are scarce. We examined the association between glucarpidase administration and outcomes in adults with MTX-AKI from 28 cancer centers across the United States using a sequential target trial emulation framework. The primary end point was kidney recovery at hospital discharge, defined as survival to discharge with serum creatinine &lt;1.5-fold baseline and without dialysis dependence. Key secondary end points were time to kidney recovery, neutropenia, and transaminitis on day 7, and time to death. Using multivariable logistic and Cox regression models, we compared outcomes in patients who received glucarpidase within 4 days following MTX initiation with those in patients who did not. Among 708 patients with MTX-AKI, 209 (29.5%) received glucarpidase. Overall, 183 (25.8%) had a primary end point event. Glucarpidase receipt was associated with a 2.70-fold higher adjusted odds of kidney recovery (95% confidence interval [CI], 1.69–4.31) compared with no glucarpidase receipt. Patients treated with glucarpidase also had faster time to kidney recovery (adjusted hazard ratio [aHR], 1.88; 95% CI, 1.18–3.33) and lower risks of grade ≥2 neutropenia (adjusted odds ratio [aOR], 0.50; 95% CI, 0.28–0.91) and grade ≥2 transaminitis (aOR, 0.50; 95% CI, 0.28–0.91) on day 7. There was no difference in time to death (aHR, 0.76; 95% CI, 0.49–1.18). These data suggest glucarpidase may improve both renal and extrarenal outcomes in patients with MTX-AKI.
Validation Of the Tau Heterogeneity Evaluation in Alzheimer’s Disease (THETA) Score Using Longitudinal and Histopathology Data
Gebre, Robel K , Raghavan, Sheelakumari , Wiste, Heather J. , Costoya‐Sánchez, Alejandro , Spychalla, Anthony J., Lowe, Val J. , Graff‐Radford, Jonathan, Petersen, Ronald C., Rial, Alexis Moscoso , Heeman, Fiona , Schwarz, Christopher G. , Graff‐Radford, Jonathan , Knopman, David S. , Petersen, Ronald C. , Schöll, Michael , Murray, Melissa E. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.091770 Get It

AbstractBackgroundWe recently developed a novel tau‐PET summary measure THETA, capturing regional heterogeneity and identifying tau status, using ground truth visual assessments from a large single‐center cross‐sectional dataset and validated on independent cohorts [1, 2]. In this study, we aimed to evaluate the performance of THETA on longitudinal and histopathology data.MethodWe included longitudinal tau‐PET ([18F]flortaucipir) data from 696 Mayo Clinic Study of Aging (MCSA) and ADRC participants, with histopathology in n = 90. Fig. 1 shows the model that uses regional standard uptake value ratios (SUVR) and a target of binary class of tau positivity for prediction of THETA. This model was applied to predict tau status on each followup scan. Slopes of the meta‐ROIs’ tau SUVRs and THETA were evaluated by diagnostic group and as a function of baseline amyloid SUVR in discordant CU participants (where meta‐ROI and visual assessments did not match at baseline) and in incident‐THETA+ CU participants (whose THETA moved from below to above 1 over serial tau‐PET scans). We evaluated tau measurements as a function of Braak stages for neurofibrillary tangles.ResultLongitudinal plots of meta‐ROIs for diagnostic groups were very similar, but the expanded range of THETA based on visual positivity prediction clearly identified tau positive or tau‐negative scans. In discordant‐CU (n = 97) and incident‐THETA+ CU participants (n = 14 all amyloid positive at follow‐up but only 65% at baseline), the relationship between baseline amyloid and rate of tau increase was stronger for THETA than temporal meta‐ROI (Fig. 2). Separation between baseline and follow‐up was greater for THETA (t‐statistics = 90) compared to temporal meta‐ROI (t‐statistics = 20) (p<0.01) in the incident‐THETA+ CU participants. THETA showed a slightly stronger association with Braak stage than meta‐ROIs (rho = 0.87 vs. ≤0.83, p<0.05), with better separation of clinical diagnoses (Fig. 3).ConclusionTHETA remained clearly negative or positive in MCI and AD, providing consistent information on underlying etiology of impairment at both baseline and follow‐up. Although binary in its construction, THETA both provided separation of values based on tau status and its change correlated with baseline amyloid burden especially in discordant‐CU where tau deposition is not in typical meta‐ROIs. Further work is needed to confirm if THETA captures early tau changes.
Cognitive screening in the emergency department: Agreement between the patient‐ and caregiver‐completed AD8
Galske, James , Sather, Anna, Chera, Tonya, Gettel, Cameron J. , Hwang, Ula , Carpenter, Christopher R.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.087105 Get It

AbstractBackgroundImpaired cognition is prevalent in older adults in the emergency department (ED), but many cases go unrecognized. The Ascertain Dementia 8 (AD8) is a validated, self‐administered screening tool that can be used by patients and caregivers to assess for early cognitive changes associated with dementia. However, little is known regarding the degree of alignment between respondents in the ED setting. Our objective was to assess the agreement between the patient‐(pAD8) versus caregiver‐completed AD8 (cAD8).MethodsWe conducted a prospective observational study of community‐dwelling older adults aged 65+ years seeking emergency care and their caregivers between October 2021 and November 2023. Patients with a diagnosis of dementia indicated in the electronic health record were excluded. Collected by trained research assistants, AD8 scores ranged from 0‐8, with scores 2+ indicating cognitive impairment. Patients and caregivers were blinded to the others’ AD8 rating. The intraclass correlation coefficient (ICC) was used to assess the agreement of the presence or absence of cognitive impairment based on pAD8 and cAD8 scores.ResultsOur analytic sample included 538 dyads, of which 34.7% of patients were male with a mean age of 73.5. A total of 132 (24.5%) patients scored themselves as cognitively impaired versus 201 (37.4%) patients were scored as cognitively impaired by their caregivers. Between groups, an ICC of 0.519 (95% CI 0.454‐0.578) demonstrated moderate agreement in identifying cognitive impairment based on pAD8 and cAD8 scores.ConclusionApproximately 1 in 4 older adults without a dementia diagnosis in the emergency department identified themselves as having cognitive impairment, with caregivers even more likely to identify cognitive impairment in accompanied older adult patients. With current guidance suggesting that the pAD8 be used in the absence of the cAD8, these findings highlight important differences to account for based on the respondent when screening for cognitive impairment.
EUS-guided gallbladder drainage vs dual stent transpapillary gallbladder drainage for management of acute cholecystitis
Amin, Dhruval , Rau, Prashanth , Cooper, Katherine M. , Sayegh, Lea N. , Mostafa, Nouran, Achebe, Ikechukwu , DeVore, Zachary, Gonzalez, Daniella, Stephanie, Stephanie , Mehta, Savant, Marshall, Christopher , Nasser‐Ghodsi, Navine , Marya, Neil B. , Cooper, Katherine M , Sayegh, Lea Nicole , Storm, Andrew C , Mostafa, Nouran, Zivny, Jaroslav, Storm, Andrew C. , Marya, Neil B.

Mayo Clinic

Endoscopy International Open | January 2, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2509-7076 | PMID 40007656 Get It

Abstract Cholecystectomy (CCY) is the standard treatment for acute cholecystitis. For non-surgical patients, percutaneous cholecystostomy tube (PT-GBD) is recommended but is associated with high readmission rates and poor quality of life. Endoscopic gallbladder decompression techniques, including endoscopic transpapillary gallbladder drainage (ET-GBD) and endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), are alternatives. Studies comparing ET-GBD and EUS-GBD have shown EUS-GBD to have superior outcomes. However, these studies assessed ET-GBD mostly via single transcystic stent placement (SSET-GBD). This study aimed to compare outcomes of dual transcystic stents (DSET-GBD) and EUS-GBD in non-surgical candidates with acute cholecystitis. A multicenter analysis was conducted on patients who underwent ET-GBD or EUS-GBD between January 2019 and January 2023. Data were extracted from electronic medical records and outcomes including technical success, success, adverse events (AEs), and recurrence rates of cholecystitis were measured. Of 129 procedures (56 EUS-GBD; 73 ET-GBD), technical success was achieved in 87.5% of EUS-GBD and 86.3% of ET-GBD attempts. Immediate clinical success was achieved in 98.1% for EUS-GBD and 100% for DSET-GBD. AE rates were similar between the groups. Recurrent cholecystitis rates were 5.3% for EUS-GBD and 8.2% for DSET-GBD (P = 0.692). This study demonstrates that DSET-GBD has similarly low rates of recurrent acute cholecystitis compared with EUS-GBD. DSET-GBD should be considered as an alternative management strategy for management of acute cholecystitis in patients who are unable to undergo CCY.
miR-217-5p NanomiRs Inhibit Glioblastoma Growth and Enhance Effects of Ionizing Radiation via EZH2 Inhibition and Epigenetic Reprogramming
Korleski, Jack , Sudhir, Sweta , Rui, Yuan , Caputo, Christopher , Johnson, Amanda , Madhvacharyula, Tanmaya, Rasamsetty, Anisha, Li, Yunqing , Lal, Bachchu, Zhou, Weiqiang , Smith-Connor, Karen, Tzeng, Stephany Y. , Laterra, John , López-Bertoni, Hernando , Johnson, Amanda L , Li, Yunqing , Zhou, Weiqiang , Tzeng, Stephany Y , Lopez-Bertoni, Hernando , Korleski, Jack , Sall, Sophie , Khela, Harmon Singh , Green, Jordan J.

Mayo Clinic

Cancers | January 1, 2025 | Volume: 17 | Issue: 1 | Pages: 80

10.3390/cancers17010080 | PMID 39796709 Get It

Background/Objectives: CSCs are critical drivers of the tumor and stem cell phenotypes of glioblastoma (GBM) cells. Chromatin modifications play a fundamental role in driving a GBM CSC phenotype. The goal of this study is to further our understanding of how stem cell-driving events control changes in chromatin architecture that contribute to the tumor-propagating phenotype of GBM. Methods: We utilized computational analyses to identify a subset of clinically relevant genes that were predicted to be repressed in a Polycomb repressive complex 2 (PRC2)-dependent manner in GBM upon induction of stem cell-driving events. These associations were validated in patient-derived GBM neurosphere models using state-of-the-art molecular techniques to express, silence, and measure microRNA (miRNA) and gene expression changes. Advanced Poly(β-amino ester) nanoparticle formulations (PBAEs) were used to deliver miRNAs in vivo to orthotopic human GBM tumor models. Results: We show that glioma stem cell (GSC) formation and tumor propagation involve the crosstalk between multiple epigenetic mechanisms, resulting in the repression of the miRNAs that regulate PRC2 function and histone H3 lysine 27 tri-methylation (H3K27me3). We also identified miR-217-5p as an EZH2 regulator repressed in GSCs and showed that miR-217-5p reconstitution using advanced nanoparticle formulations re-activates the PRC2-repressed genes, inhibits GSC formation, impairs tumor growth, and enhances the effects of ionizing radiation in an orthotopic model of GBM. Conclusions: These findings suggest that inhibiting PRC2 function by targeting EZH2 with miR-217-5p advanced nanoparticle formulations could have a therapeutic benefit in GBM.
Modular dual-mobility constructs outperformed large femoral heads in 299 revision total hip arthroplasties at mid-term follow-up
Carender, Christopher N. , Fruth, Kristin M. , Taunton, Michael J. , Pagnano, Mark W., Taunton, Michael J , Bedard, Nicholas A. , Pagnano, Mark W. , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | January 1, 2025 | Volume: 107-B | Issue: 1 | Pages: 58-64

10.1302/0301-620x.107b1.bjj-2024-0170.r1 | PMID 39743935 Get It

AimsThe purpose of this study was to directly compare the Modular Dual Mobility (MDM) Mobile Bearing Hip System (Stryker, USA) and large femoral heads (LFHs) in revision total hip arthroplasties (THAs) at mid-term follow-up, with specific emphasis on survival free of re-revision for dislocation, any re-revision, dislocation, and the risk of metal-related complications.MethodsWe identified 299 revision THAs performed at a single tertiary care academic institution from March 2011 to July 2014. Aseptic loosening of the acetabular component (n = 65), dislocation (n = 58), and reimplantation as part of a two-stage exchange protocol (n = 57) were the most common reasons for index revision. MDM constructs were used in 123 cases, and LFHs were used in 176 cases. Mean age was 66 years (28 to 93), mean BMI was 31 kg/m2 (18 to 55), and 45% (n = 136) were female. Mean follow-up was seven years (2 to 12).ResultsThe ten-year survival free of re-revision for dislocation was 99% (95% CI 95 to 100) in the MDM cohort and 91% (95% CI 84 to 96) in the LFH cohort, with a significantly increased risk of re-revision for dislocation in the LFH cohort (HR 7.1 (95% CI 1.3 to 40.8); p = 0.023). The ten-year survival free of any re-revision was 92% (95% CI 82 to 99%) in the MDM cohort and 84% (95% CI 74 to 90) in the LFH cohort with a significantly increased risk of any re-revision in the LFH cohort (HR 2.6 (95% CI 1.1 to 5.9); p = 0.024). The ten-year survival free of any dislocation was 95% (95% CI 85 to 99) in the MDM cohort and 87% (95% CI 78 to 92) in the LFH cohort with a significantly increased risk of any dislocation in the LFH cohort (HR 2.7 (95% CI 1.1 to 6.3); p = 0.028). There were no re-revisions or reoperations for metallosis or corrosion in the MDM cohort.ConclusionIn this head-to-head comparison, revision THAs with a MDM construct safely and effectively lowered the risk of re-revision for dislocation, any re-revision, and any dislocation compared to LFH at mid-term follow-up. There were no re-revisions or reoperations for metallosis or corrosion in the MDM cohort.Cite this article: Bone Joint J 2025;107-B(1):58–64.